# A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Source: https://onco.cc/trials/nct03033511/  
OnCo record `nct03033511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rovalpituzumab tesirine and Dexamethasone in Small-cell lung cancer, run by AbbVie, recorded as terminated on the registry.

## Summary

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) is a phase 3 interventional study registered as NCT03033511 by AbbVie, with 748 participants recorded, started 2017-02-07 and due to reach its primary completion in 2019-11-20. Interventions recorded: Placebo for dexamethasone, Placebo for rovalpituzumab tesirine, Rovalpituzumab tesirine, Dexamethasone. Conditions recorded: Small Cell Lung Cancer.

Linked to the drug Rovalpituzumab tesirine because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03033511
- Phase: 3
- Setting: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
- Sponsor: AbbVie
- Enrolled: 748

## Sources

- ClinicalTrials.gov NCT03033511: https://clinicaltrials.gov/study/NCT03033511

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Rovalpituzumab tesirine](https://onco.cc/drugs/rovalpituzumab-tesirine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03033511.json